Amgen (AMGN)
(Delayed Data from NSDQ)
$305.84 USD
-0.66 (-0.22%)
Updated May 24, 2024 04:00 PM ET
After-Market: $305.35 -0.49 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Brokerage Reports
Amgen Inc. [AMGN]
Reports for Purchase
Showing records 401 - 420 ( 429 total )
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
ODAC panel not swayed by Xgeva BMFS data - vote 12-1 against approving indication; SELL
Provider: LAZARD
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Xgeva/Prolio likely to become key growth driver ahead & expected to drive high single digit earnings growth...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Xgeva/Prolio likely to be a key driver & help record high single-digit earnings growth...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Modest topline growth & high single digit EPS growth expected over next five years, driven by approval of Prolia (denosumab) in cancer & Part D reimbursement coming online in early CY11....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Company: Amgen Inc.
Industry: Medical - Biomedical and Genetics
Likely approval of Prolia (denosumab) in cancer to ensure modest topline growth & mid-to-high single digit EPS growth over next five years....
Provider: FIRST GLOBAL
Analyst: THOMAS K